Emergent BioSolutions Statistics

Total Valuation

FRA:ER4 has a market cap or net worth of EUR 542.68 million. The enterprise value is 907.55 million.

Market Cap	542.68M
Enterprise Value	907.55M

Important Dates

The next estimated earnings date is Thursday, March 5, 2026.

Earnings Date	Mar 5, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	52.52M
Shares Outstanding	n/a
Shares Change (YoY)	+6.86%
Shares Change (QoQ)	+4.24%
Owned by Insiders (%)	2.86%
Owned by Institutions (%)	72.84%
Float	51.02M

Valuation Ratios

The trailing PE ratio is 8.39.

PE Ratio	8.39
Forward PE	n/a
PS Ratio	0.81
PB Ratio	1.09
P/TBV Ratio	4.91
P/FCF Ratio	454.80
P/OCF Ratio	48.98
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 4.81, with an EV/FCF ratio of 760.59.

EV / Earnings	14.03
EV / Sales	1.34
EV / EBITDA	4.81
EV / EBIT	8.54
EV / FCF	760.59

Financial Position

The company has a current ratio of 5.76, with a Debt / Equity ratio of 1.15.

Current Ratio	5.76
Quick Ratio	2.89
Debt / Equity	1.15
Debt / EBITDA	3.05
Debt / FCF	479.29
Interest Coverage	2.09

Financial Efficiency

Return on equity (ROE) is 13.92% and return on invested capital (ROIC) is 6.35%.

Return on Equity (ROE)	13.92%
Return on Assets (ROA)	5.27%
Return on Invested Capital (ROIC)	6.35%
Return on Capital Employed (ROCE)	9.35%
Revenue Per Employee	747,088
Profits Per Employee	71,877
Employee Count	900
Asset Turnover	0.54
Inventory Turnover	1.19

Taxes

In the past 12 months, FRA:ER4 has paid 25.57 million in taxes.

Income Tax	25.57M
Effective Tax Rate	28.33%

Stock Price Statistics

The stock price has increased by +11.37% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+11.37%
50-Day Moving Average	8.68
200-Day Moving Average	6.48
Relative Strength Index (RSI)	63.89
Average Volume (20 Days)	65

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	8.53

Income Statement

In the last 12 months, FRA:ER4 had revenue of EUR 672.38 million and earned 64.69 million in profits. Earnings per share was 1.15.

Revenue	672.38M
Gross Profit	327.54M
Operating Income	105.60M
Pretax Income	90.26M
Net Income	64.69M
EBITDA	187.51M
EBIT	105.60M
Earnings Per Share (EPS)	1.15

Full Income Statement

Balance Sheet

The company has 209.24 million in cash and 571.89 million in debt, giving a net cash position of -362.65 million.

Cash & Cash Equivalents	209.24M
Total Debt	571.89M
Net Cash	-362.65M
Net Cash Per Share	n/a
Equity (Book Value)	496.46M
Book Value Per Share	9.42
Working Capital	554.34M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 11.08 million and capital expenditures -9.89 million, giving a free cash flow of 1.19 million.

Operating Cash Flow	11.08M
Capital Expenditures	-9.89M
Free Cash Flow	1.19M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 48.71%, with operating and profit margins of 15.71% and 9.62%.

Gross Margin	48.71%
Operating Margin	15.71%
Pretax Margin	13.42%
Profit Margin	9.62%
EBITDA Margin	27.89%
EBIT Margin	15.71%
FCF Margin	0.18%

Dividends & Yields

FRA:ER4 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-6.86%
Shareholder Yield	-6.86%
Earnings Yield	11.92%
FCF Yield	0.22%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:ER4 has an Altman Z-Score of 1.54 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.54
Piotroski F-Score	5